Thrombophilia testing in patients receiving rivaroxaban or apixaban for the treatment of venous thromboembolism

Thromb Res. 2020 Nov:195:231-232. doi: 10.1016/j.thromres.2020.07.052. Epub 2020 Jul 30.
No abstract available

Keywords: Activated protein C resistance; Apixaban; Lupus coagulation inhibitor; Rivaroxaban; Venous thromboembolism.

Publication types

  • Letter

MeSH terms

  • Administration, Oral
  • Anticoagulants / adverse effects
  • Factor Xa Inhibitors / adverse effects
  • Humans
  • Pyrazoles
  • Pyridones / adverse effects
  • Rivaroxaban / adverse effects
  • Thrombophilia* / drug therapy
  • Venous Thromboembolism* / drug therapy

Substances

  • Anticoagulants
  • Factor Xa Inhibitors
  • Pyrazoles
  • Pyridones
  • apixaban
  • Rivaroxaban